12,495 Shares in 10x Genomics $TXG Bought by Tactive Advisors LLC

Tactive Advisors LLC bought a new position in shares of 10x Genomics (NASDAQ:TXG) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund bought 12,495 shares of the company’s stock, valued at approximately $479,000.

Other institutional investors have also recently made changes to their positions in the company. Elevation Wealth Partners LLC lifted its stake in shares of 10x Genomics by 332.3% in the second quarter. Elevation Wealth Partners LLC now owns 1,487 shares of the company’s stock worth $57,000 after acquiring an additional 1,143 shares during the period. 55 North Private Wealth LLC bought a new stake in shares of 10x Genomics in the 2nd quarter valued at $312,000. Grant Private Wealth Management Inc bought a new stake in shares of 10x Genomics in the 2nd quarter valued at $292,000. Edgestream Partners L.P. bought a new position in 10x Genomics during the first quarter worth $1,233,000. Finally, Bull Harbor Capital LLC bought a new position in 10x Genomics during the first quarter worth $248,000. Institutional investors own 84.68% of the company’s stock.

10x Genomics Price Performance

NASDAQ TXG opened at $52.03 on Monday. The company has a market cap of $6.61 billion, a price-to-earnings ratio of -88.18 and a beta of 2.03. 10x Genomics has a 52 week low of $11.16 and a 52 week high of $52.22. The business has a 50 day moving average price of $39.28 and a 200-day moving average price of $27.67.

10x Genomics (NASDAQ:TXG) last issued its earnings results on Thursday, August 6th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.10. 10x Genomics had a negative return on equity of 9.41% and a negative net margin of 12.18%.The company had revenue of $151.04 million for the quarter, compared to analysts’ expectations of $146.67 million. During the same period last year, the business earned $0.28 EPS. 10x Genomics’s quarterly revenue was down 12.7% compared to the same quarter last year. On average, equities research analysts anticipate that 10x Genomics will post -0.78 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have weighed in on TXG. Weiss Ratings reiterated a “sell (d-)” rating on shares of 10x Genomics in a report on Wednesday, June 24th. Bank of America raised their target price on 10x Genomics from $21.00 to $30.00 and gave the stock a “neutral” rating in a research note on Monday, April 20th. Leerink Partners boosted their price target on 10x Genomics from $23.00 to $40.00 and gave the company a “market perform” rating in a research note on Friday, July 17th. Piper Sandler raised their price objective on shares of 10x Genomics from $20.00 to $42.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 1st. Finally, Zacks Research downgraded shares of 10x Genomics from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 18th. Four research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $34.83.

Insider Buying and Selling at 10x Genomics

In related news, Director Shehnaaz Suliman sold 5,723 shares of the company’s stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $32.63, for a total value of $186,741.49. Following the sale, the director owned 31,722 shares in the company, valued at $1,035,088.86. This represents a 15.28% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Benjamin J. Hindson sold 11,595 shares of the firm’s stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $24.44, for a total transaction of $283,381.80. Following the completion of the transaction, the insider directly owned 502,000 shares in the company, valued at approximately $12,268,880. The trade was a 2.26% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 91,309 shares of company stock valued at $2,581,357 over the last three months. Corporate insiders own 8.84% of the company’s stock.

More 10x Genomics News

Here are the key news stories impacting 10x Genomics this week:

• Positive Sentiment: Q2 results exceeded expectations: 10x Genomics reported an adjusted loss of $0.14 per share, better than the $0.23–$0.24 consensus loss, while revenue of $151.0 million topped estimates near $146.7 million. 10x Genomics Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: 2026 outlook was raised: Management now expects full-year revenue of $610 million to $630 million, with the midpoint slightly above Wall Street’s approximately $613.8 million forecast. The guidance increase signals confidence in demand and supports the stock’s positive reaction. 10x Genomics Raises 2026 Revenue Outlook
• Positive Sentiment: Gross margin improved: Expansion in gross margin adds to the earnings beat and suggests improving operating leverage, even though the company remains unprofitable.
• Neutral Sentiment: Atera shipments remained around 40 units: The company maintained this shipment level while raising its outlook, but investors may be watching for further acceleration in instrument placements. 10x Genomics Q2 2026 Earnings Call Transcript
• Negative Sentiment: Sales and earnings remain pressured year over year: Revenue declined 12.7% from the prior-year quarter, and the company posted a loss versus prior-year EPS of $0.28. Continued losses and an expected full-year loss remain risks despite the improved outlook.

10x Genomics Company Profile

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.